WebWire | News by Industry : Medical / Pharmaceuticals

Sanofi Foundation opens new chapter centered on future generations

Thu, 25 Jun 2026 13:04:01 EDT

The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases. Through the Foundation, Sanofi extends its commitment to improving people's lives beyond healthcare by supporting younger generations facing some of today's most pressing health, climate, and humanitarian challenges. - - “The challenges facing younger generations today extend far beyond access to healthcare alone. By strengthening th...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356768

Socioeconomic Challenges Color Patients' Lung Cancer Screening Experience

Wed, 24 Jun 2026 11:00:53 EDT

New research among lung cancer screening participants has found that low-dose chest computed tomography (CT) screening is generally well tolerated both physically and emotionally, but experiences vary across socioeconomic groups. Lower-income and safety-net participants experienced higher testing-related burden, with factors such as insurance and employment status associated with more discomfort or anxiety. The findings in the Journal of the American College of Radiology, published by...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356712

Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Tue, 23 Jun 2026 11:23:27 EDT

- - • Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) - • Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms - • ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life - - - - The Ministry of Health, Labour and Welfare in Japan has granted marketing...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356666

Are certain demographic, birth, and parental characteristics linked to an increased risk of early-onset colorectal cancer?

Tue, 23 Jun 2026 10:57:24 EDT

A recent study found that factors such as a person's birthweight, sex, ethnicity, and father's age may affect the risk of being diagnosed with colorectal cancer at a young age. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. - - In the study of 1,221 people born and diagnosed with early-onset colorectal cancer—defined as being diagnosed before age 50—in California in 1988–2021 and 61,050 matched individuals without cancer, m...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356655

Sanofi appoints Paulo Fontoura as Global Head of R&D

Mon, 22 Jun 2026 19:21:08 EDT

Sanofi today announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President, Global Head of Research & Development Pharma, effective September 1, 2026. He will be a member of Sanofi's Executive Committee, based in Paris, and will report to Chief Executive Officer Bel�n Garijo. As head of R&D Pharma, Paulo will lead Sanofi's end-to-end innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs, with responsibility for...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356626

AdvaMed Earns WTOP News Regional Top Workplaces 2026 Award, Culture Excellence Awards

Mon, 22 Jun 2026 08:27:24 EDT

AdvaMed, the largest trade association representing medtech innovators, announced it is a WTOP News Top Workplaces 2026 award winner in the Washington, D.C., region and received five Culture Excellence awards. - - “Our strong work culture flows from our highly motivating mission: access to life-saving, life enhancing medtech for every patient,” said Scott Whitaker, President and CEO of AdvaMed, the Medtech Association. “That mission drives the work we do every day on behalf of our member...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356602

Senate panel passes NO FAKES Act; AMA urges Congressional approval

Mon, 22 Jun 2026 08:16:18 EDT

Statement attributable to: - John Whyte, MD, MPH - CEO, American Medical Association - - “The NO FAKES Act is the real deal—an important step toward ensuring that innovation serves people, not those seeking to deceive them. Artificial intelligence has tremendous potential to improve healthcare, but we are already seeing bad actors use AI-generated content to impersonate trusted voices, spread misinformation, and promote unproven treatments that can put patients at risk. - - “Patients deser...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356599

Vali Health Raises $6M to Build Responsible AI Infrastructure for Home Care Agencies

Wed, 17 Jun 2026 09:35:05 EDT

Vali Health, a startup building responsible AI infrastructure for the home care industry, today emerged from stealth with $6 million in funding from Bonfire Ventures, Supernode, Comma Capital, along with Jacquelyn Kung, an industry veteran who built two of the largest software platforms for home care. Vali's AI agents enable home care agencies to automate workforce management and coordination, while maintaining trust and safety front and center. - - Home Care's Opportunity: A Mission-Crit...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356384

Heartseed Announces First Patient Dosed in a Phase I/II EMERALD Study with HS-005 – a Cell Therapy Administered via Catheter, Designed to Restore Heart Function in People with Severe Heart Failure

Mon, 15 Jun 2026 12:16:05 EDT

Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation (Nikon), manufactures iPSC-derived purified cardiomyocyte spheroids of HS-005, under contract to Heartseed Inc.(Heartseed). - - Heartseed today announced that the successful dosing of the first patient in its domestic phase I/II clinical trial (EMERALD Study) of HS-005 which utilizes a catheter system for endocardial delivery to administer cardiomyocyte spheroids for patients with severe heart failure with reduced eje...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356264

CONV2X Announces Smart Technology Transformation in Healthcare & Life Sciences Summit in New York City

Mon, 15 Jun 2026 10:56:45 EDT

CONV2X Smart Technology Transformation in Healthcare & Life Sciences, announced its annual two-day executive summit taking place October 29–30, 2026 at the Historic GE Building, ILR Conference Center, 570 Lexington Avenue, New York, NY. - - Themed Beyond the Pilot, the conference addresses a defining challenge of 2026: healthcare implementation — deploying AI, telehealth, and smart technology at enterprise scale with measurable outcomes, sustainable economics, and sound governance. - - Op...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356147

Elsevier launches Ebola Information Center with free clinical and research resources to support response to outbreak

Mon, 15 Jun 2026 10:54:14 EDT

Following the World Health Organization's declaration of an Ebola outbreak caused by Bundibugyo virus in the Democratic Republic of Congo and Uganda as a Public Health Emergency of International Concern (PHEIC), Elsevier, a global leader in scientific information and analytics, has launched its Ebola Information Center to provide healthcare professionals, researchers, policy makers and the public with free access to critical clinical and research information to support the global respon...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356256

Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

Mon, 15 Jun 2026 10:48:37 EDT

Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks - - If approved, Ultomiris would be the first C5 complement inhibitor available for this rare kidney disease - - Alexion, AstraZeneca Rare Disease's supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab) has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356253

Caring for non-communicable diseases during pregnancy, expert convening

Mon, 15 Jun 2026 10:36:28 EDT

The World Health Organization (WHO) is developing new recommendations to improve care for pregnant and postpartum women living with noncommunicable diseases (NCDs). - - Around the world, more pregnancies are being affected by NCDs such as diabetes, high blood pressure, heart conditions, obesity and other long-term health problems. These conditions may already exist before pregnancy or develop during it. NCDs are now a major cause of poor health among women of reproductive age and are incr...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356247

“Beyond Feet on Fire” is Free to Download for Only Five Days (Until 6/19/26)

Mon, 15 Jun 2026 06:00:00 EDT

Best Seller Publishing announces the release of Dr. Paul Fisher's new book, “Beyond Feet on Fire: How To Reverse Neuropathy Without Drugs and Surgery.” It will be available in the Amazon store for free for only five days. - - “Beyond Feet on Fire” is about understanding neuropathy as more than just a nerve disorder—it is a complex breakdown involving metabolism, circulation, and neurological communication. Drawing on years of clinical experience and extensive research, Dr. Paul Fishe...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356184

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Fri, 12 Jun 2026 10:38:47 EDT

• Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. - • Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 - • Over half a million eyes worldwide have already experienced clearer, extended range of vision with TECNIS PureSee IOL after cataract surgery.3,4 - • 9...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356176

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Wed, 10 Jun 2026 18:17:01 EDT

Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped. This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy. No safety signals related to riliprubart were identified as part of this interim a...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356074

Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - May 2026

Wed, 10 Jun 2026 09:20:39 EDT

At the mid-way point of Immunization Agenda 2030 (IA2030), countries gathering at the Seventy-ninth World Health Assembly (WHA79) marked an important moment in reaffirming their commitment to reaching everyone, everywhere with life-saving vaccines. - - Member States and global health partners strongly reasserted their support for the strategy, goals, and programmatic implementation of IA2030, recognizing immunization as one of the most powerful, cost-effective and equitable health interv...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=356034

AMA adopts new policies to improve affordable access to obesity treatments

Tue, 9 Jun 2026 09:02:36 EDT

Physicians and medical students convened for the Annual Meeting of the American Medical Association's (AMA) House of Delegates today and adopted new policies aimed at improving patient access to evidence-based obesity treatments while advancing broader efforts to address prescription drug affordability and insurance coverage barriers. - - The new policies build upon longstanding AMA policy supporting affordable access to prescription medications, prescription drug price transparency, pharma...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355989

3D-printed devices could streamline the production of drug-delivery microparticles

Tue, 9 Jun 2026 08:39:59 EDT

MIT researchers have demonstrated a low-cost design of specialized electronic nozzles, called triaxial electrospray emitters, that could be used to manufacture time-release drug-delivery particles or self-healing materials efficiently and at scale. - - Triaxial electrospray emitters use electricity to precisely dispense three liquids from microscopic nozzles to generate a steady stream with three distinct fluid layers. The liquid forms multilayered droplets, which can solidify into layered...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355980

Wiley Launches Advanced Brain to Push Disciplinary Boundaries Across Neuroscience & Related Fields

Tue, 9 Jun 2026 08:08:00 EDT

Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence, today announced the launch of Advanced Brain, an open access, interdisciplinary journal dedicated to publishing cutting-edge research across neuroscience, neurology, psychiatry and psychology. The new journal, part of Wiley's Advanced Portfolio of high-impact collaborative journals, is now open for submissions. - - Advanced Brain is designed to further both fundamental and applied understanding of the...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355967

Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Mon, 8 Jun 2026 10:37:39 EDT

Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector - - - • Sarclisa administered via the CirCLIQ ® OBI offers a treatment experience designed around the needs of patients and HCPs and enables flexible administration in either home or outpatient settings - • Sarclisa is the first anticancer treatment to be administered through an OBI and the first MM treatment available by both SC OBI and manual injection in the EU - •...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355917

Thrifty Food Plan Costs Vary Widely Across US Regions and Cities

Mon, 8 Jun 2026 09:58:55 EDT

A recent study in the Journal of Nutrition Education and Behavior (JNEB), published by Elsevier, examined how the cost of the USDA's Thrifty Food Plan (TFP), which serves as the basis for determining maximum SNAP benefits, varied across geographic regions, metropolitan areas, and seasons from 2012 to 2018. Researchers found that where a household is located plays a much larger role in the cost of a healthy diet than year-to-year inflation. - - Researchers used USDA Food-at-Home Monthl...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355898

Can taking aspirin uncover asymptomatic bladder cancer?

Fri, 5 Jun 2026 09:21:01 EDT

The presence of blood cells in urine is a sign of bladder cancer. Because aspirin blocks platelets from forming harmful blood clots, the medication can cause mild bleeding or worsen existing bleeding in the urinary tract. Results from a study in the Journal of Internal Medicine suggest that this may prompt a clinician to run tests that uncover an asymptomatic bladder tumor. - - For the study, investigators analyzed information on 50,771 Danish adults who started taking aspirin in 2005–2...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355816

GEODIS to enhance its pharmaceutical logistics capabilities and move into a new temperature controlled, GDP compliant warehouse in Manchester

Thu, 4 Jun 2026 10:28:06 EDT

GEODIS, a world leader in transport and logistics, announces the opening of a temperature-controlled GDP-compliant pharmaceutical warehouse close to the airport in Manchester designed to support both inventory management and cross-docking operations, reinforcing its capabilities in the fast-growing Pharma & Healthcare sector in the UK and Ireland. The facility is scheduled to go live on June 1st, 2026. - - The warehouse will offer 2,000 pallet positions and has been developed to accommodate...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355773

Sanofi launches 2026 global employee stock purchase plan

Thu, 4 Jun 2026 10:25:32 EDT

Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company's growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, a...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355771

Kaiser Permanente names Emily Holliman president of Mid-Atlantic States region

Wed, 3 Jun 2026 10:07:22 EDT

Kaiser Permanente has appointed Emily Holliman as president of Kaiser Permanente in the Mid-Atlantic States, effective immediately. Holliman has served as the region's interim president since June 2025, leading efforts to provide high-quality, integrated health care and coverage to the organization's 750,551 members across 35 medical centers in Maryland, Virginia, and Washington, D.C. - - A proven health care leader with more than 20 years of experience, Holiman brings deep experience in...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355699

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Wed, 3 Jun 2026 10:03:16 EDT

� Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function - - � Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg group a - - � ...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355698

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

Tue, 2 Jun 2026 10:54:17 EDT

The U.S. Food and Drug Administration (FDA) today issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge. - - When finalized, the guidance will outline how sponsors can use publicly available information and established platform knowledge, including chemistry, manufacturing and controls (CMC) data, nonclinical study results and clinical information, to streamline regulatory...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355643

Study Links Cannabis and Tobacco Co-Use to Lower Brain Performance in At-Risk Adolescents

Tue, 2 Jun 2026 10:50:35 EDT

New research shows that among people at clinical high risk for psychosis, cannabis and tobacco co-use was associated with lower cognitive performance compared to healthy controls. The novel study appearing in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier, fills a critical gap in research, providing clinicians and scientists with vital new insights into the risks associated with cannabis and tobacco co-use and the potential impact on vulnerable a...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355642

AMA statement on EO directing CDC to assess childhood vaccine schedule

Mon, 1 Jun 2026 12:15:33 EDT

Statement attributable to: - Bobby Mukkamala, MD - President, American Medical Association - - “There is no credible scientific evidence to support changing the current childhood vaccine schedule. That schedule is built on decades of rigorous research and real-world data, and it is designed to protect children in the U.S. when they are most vulnerable based on our nation's disease burden. - - “Altering it without clear, evidence-based justification risks continued confusion for parents and...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355567

WHO launches new guide to help scale psychological self-help

Mon, 1 Jun 2026 12:00:08 EDT

Psychological self-help interventions: delivering self-help for individuals, featuring Step-by-Step and Doing What Matters in Times of Stress provides practical advice on planning, adapting and delivering self-help, with or without support from trained non-specialists. More than one billion people worldwide live with a mental health condition, yet many lack access to effective care. Psychological self-help interventions are one way to help close this gap, offering structured techniques...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355562

Dr. Ashish Jha Headlines ConV2X Smart Technology Transformation Summit - NYC Oct 2026

Mon, 1 Jun 2026 08:00:00 EDT

Partners in Digital Health today announced that Dr. Ashish Jha, one of the most influential voices in modern healthcare policy and public health leadership, will headline ConV2X Smart Technology Transformation in Healthcare & Life Sciences, taking place October 29–30, 2026, at the Historic GE Building: ILR Conference Center in New York City. - - Dr. Jha serves as Senior Fellow at the Harvard Belfer Center and Co-Founder & CEO of BioRadar. He previously served as White House COVID-19 Respo...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355445

CONV2X Decentralized Health & Life Science Summit Releases FIRST SPEAKER COHORT

Mon, 1 Jun 2026 08:00:00 EDT

Partners in Digital Health is proud to announce the first speaker cohort for ConV2X Decentralized Health — a landmark gathering of innovators, clinicians, technologists, and policy leaders reimagining the future of healthcare through decentralized infrastructure. - - This inaugural cohort represents some of the most consequential voices at the intersection of blockchain, AI, digital health, and regulatory science: - - Ajaz Hussain — Former Deputy Director, Office of Pharmaceutical S

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355173

1 in 3 Women Don't Know Menopause and Bone Loss Are Connected, New Osteoboost Data Reveals

Thu, 28 May 2026 12:00:00 EDT

Osteoboost Health, the developer of the first and only FDA-cleared prescription medical device for low bone density, today released its inaugural State of Bones Report, designed to shine a light on the perspectives and experiences of women and their bone health as they enter the perimenopause-menopause transition and beyond. - - The report is based on an independent surv

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355386

Disney and Philips Bring Beloved Storytelling and Innovative Technology to Support Kids Undergoing MRI Exams

Thu, 28 May 2026 11:43:22 EDT

The Walt Disney Company and Philips today announced that beloved Disney animated characters and stories are being incorporated directly into Philips Ambient Experience for MRI at medical facilities in 87 countries worldwide. For many children, this type of immersive environment can help shift attention away from the clinical setting, creating a more comforting and engaging experience during scans and helping more children complete their exams successfully. - - “At Disney, we believe storie...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355439

Scars of Life: Study Shows Impact of Atopic Dermatitis on Educational and Career Choices

Thu, 28 May 2026 11:32:40 EDT

Atopic dermatitis (AD), the most common form of eczema, impacts patients' life trajectories beyond the physical scars. A novel study shows that adults with AD, particularly those with childhood onset, report significantly greater limitations in their educational and professional choices, with up to 38% of childhood-onset patients reporting career restrictions and more than 36% reporting constrained study choices, compared to individuals whose disease began in adulthood. The findings of t...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355435

Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Thu, 28 May 2026 09:37:11 EDT

The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder. - - If approved, venglustat would become the first treatment available in the US to address the progressive neurological manifestations associated with GD3 and expand Sanofi's portfolio of treatment options for pati...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355412

MindMaze Therapeutics Chooses Connect Labs by Wexford at Charlotte's The Pearl Innovation District for U.S. Headquarters to Advance Neurological Care

Thu, 28 May 2026 09:00:00 EDT

MindMaze Therapeutics, a pioneer in precision neurotherapeutics, has announced a U.S headquarters at The Pearl, Charlotte's Innovation District, a partnership between Atrium Health and Wexford Science & Technology, LLC. MindMaze has built a patient experience lab within Connect Labs by Wexford, a flexible, scale-in-place lab and innovation infrastructure that facilitates frictionless entry into the Charlotte innovation ecosystem. The neurotherapy company joins world-class companies a...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=355378